Abstract: Voltage-gated sodium channels are integral for various physiologic processes including neurological signaling and cardiac contractility in humans. Classically a target to regulate cardiac arrhythmias, sodium channel agonists have held special interest as pharmacologic targets for pain management. However, the lack of receptor selectivity and specificity have resulted in various unwanted side effects and limited therapeutic ranges for nonspecific sodium channel agonists. Recently, suzetrigine, a voltage gated sodium channel subtype (NaV 1.8) selective agonist has been released and utilized for acute pain management with promising results. In this manuscript we highlight the physiology and pathology of voltage gated sodium channels along with current pharmacologic options in regards to its potential role for chronic pain management. Keywords: voltage gated sodium channels, pharmacology, neuropathic pain, chronic pain
Lam et al. (Sun,) studied this question.